## ⚠ Content Warning

This report covers topics classified as sensitive (health). Information is aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before acting on any information here.

---
last_verified: "2026-05-19T16:02:14.285Z"
---
schema_type: "SoftwareApplication"
entity_type: "Mobile Application"
app_name: "Glucose Buddy Diabetes Tracker"
developer_entity: "Azumio Inc."
bundle_id: "com.OneAppOneCause.GlucoseBuddy"
app_store_id: "294754639"
google_play_id: "com.skyhealth.glucosebuddyfree"
category: "Medical"
primary_platform: "ios"
primary_monetization: "Subscription"
offline_capable: false
market_region: "US"
platforms: "iOS & Android"
app_last_updated: "2026-04-26"
report_date: "2026-05-19"
last_verified: "2026-05-19"
report_version: "5.442"
total_reviews: 39132
overall_rating: 3.87
sentiment: "Upset"
sentiment_score: 15
confidence: "high"
confidence_score: 0.8
top_praise_theme: "Comprehensive health tracking features allow users to monitor glucose and blood pressure effectively"
top_complaint_theme: "Persistent application crashes and loading failures prevent access to critical health data"
top_request_theme: "Seamless integration with third-party health platforms for data synchronization and backup"
review_sample_size: 101
total_review_count: 101
analyzed_review_count: 87
data_age_days: 0
momentum_velocity: "maintenance"
intelligence_version: 3
nemesis: "mySugr - Diabetes Tracker Log"
competitor_count: 7
tags: ["medical", "subscription", "upset sentiment", "mobile app", "app review", "app analysis", "individuals", "managing", "diabetes"]
canonical_url: "https://marlvel.ai/intel-report/medical/com-oneapponecause-glucosebuddy"
license: "CC-BY-NC 4.0"
content_version: "v2"
---

# Glucose Buddy Diabetes Tracker App Audit

## TL;DR {#tldr}

- **Category**: Medical · Subscription
- **Signal**: Rating 3.87 · Sentiment Upset
- **Recent focus**: Persistent application crashes and loading failures prevent access to critical health data (top complaint) · Comprehensive health tracking features allow users to monitor glucose and blood pressure effectively (top praise) · Seamless integration with third-party health platforms for data synchronization and backup (top request)

> **TL;DR:** Glucose Buddy Diabetes Tracker is a medical app by Azumio Inc., rated 3.87/5 by 39.1K users, with Upset user sentiment (15/100), available on iOS & Android.
>
> **Marlvel.ai App Intelligence** — Independent analysis. US Market. No publisher influence.

<!-- speakable-start -->
> **Key Insight:** Glucose Buddy Diabetes Tracker faces Upset user sentiment (3.87/5 from 39.1K reviews), with persistent application crashes and loading failures prevent access to critical health data as the primary user concern.
<!-- speakable-end -->

## Quick Facts

| Fact | Value |
| :--- | :--- |
| **Rating** | 3.87/5 (39.1K reviews) |
| **User Mood** | Upset |
| **Category** | Medical |
| **Developer** | Azumio Inc. |
| **Pricing** | Subscription |
| **Platforms** | iOS & Android |
| **Confidence** | High (0.8/1.0) |
| **Data Age** | 0d |

## Metadata & Market Performance
- **Publisher:** Azumio Inc.
- **Category:** Medical
- **Target Audience:** Individuals managing diabetes who require consistent blood glucose tracking, carb logging, and professional health guidance.
- **Platforms:** iOS & Android
- **Version Audited:** 5.442
- **Audit Date:** 2026-05-19
- **Signal Count:** 101 reviews analyzed
- **Confidence:** High (0.8/1.0)
- **App Store ID (iOS):** 294754639
- **Bundle ID:** com.OneAppOneCause.GlucoseBuddy
- **Google Play ID:** com.skyhealth.glucosebuddyfree
- **Performance Trend:** Declining
- **Data Window:** Analysis based on signals collected up to 2026-05-19
- **Short Description:** Track blood glucose, A1C, carbs, medication, exercise, and more all in one app!

<!-- section:executive-snapshot -->
## Executive Snapshot
**What it is:** Glucose Buddy is a diabetes management app for iOS and Android that tracks blood glucose, A1C, and medication.
**Why users hire it:** Users hire the app to centralize chronic health data for physician reporting and long-term trend analysis.
<!-- /section:executive-snapshot -->

<!-- section:features -->
## App DNA (Features & Intent)
- **[Differentiator] Glucose Meter Integration:** Direct data sync with Agamatrix Jazz Wireless 2 and Dexcom devices
  * *User Intent:* Users expect seamless access across multiple devices.
- **[Differentiator] Automatic A1C Calculator:** Calculates long-term blood sugar trends based on logged entries
- **[Differentiator] Professional Coaching:** One-on-one support from certified diabetes educators via messaging
  * *User Intent:* Users seek enhanced value through premium features.
<!-- /section:features -->

<!-- section:market-position -->
## Market Position {#market-position}

Glucose Buddy ranks #48 Grossing in the US Medical category, but the 2.25★ Android rating against a 4.8★ iOS rating indicates a fragmented user experience. The grossing rank significantly trails the app's long-standing market presence, signaling that monetization friction is outpacing user value.
<!-- /section:market-position -->

## Monetization Strategy
- **Model:** Subscription
- **Tiers:** Free tier with ad support, Premium tier starting at $19/month
- **Analysis:** Subscription model anchored at $19/month, utilizing a freemium funnel to upsell coaching and advanced analytics.

<!-- section:sentiment -->
## 🔴 User Sentiment (High Confidence: 87 of 101 reviews analyzed) {#user-sentiment}
- **Overall Rating:** 3.87/5
- **Platform Split:** iOS 4.8/5 (24.6K ratings) | Android 2.3/5 (14.6K ratings)
- **Overall Sentiment:** Upset

### Top Praises
- **Comprehensive health tracking features allow users to monitor glucose and blood pressure effectively**

### Top Complaints (Impact Areas)
- **Persistent application crashes and loading failures prevent access to critical health data**
- **Aggressive subscription prompts and paywalls frustrate users attempting to access basic functionality**

### Top Requests (What Users Want)
- **Seamless integration with third-party health platforms for data synchronization and backup**

<!-- /section:sentiment -->
<!-- section:swot -->
## SWOT Analysis {#swot}

**Core Strengths:**
- 15-year market presence builds significant trust
- Direct hardware integration creates high switching costs

**Critical Frictions:**
- 2.25★ Android rating vs 4.8★ iOS rating
- Persistent launch-time crashes on latest versions
- Unresponsive customer support for billing issues

**Growth Levers:**
- Untapped B2B partnerships with health systems
- Expansion into comorbid condition tracking

**Market Threats:**
- mySugr's 12-update cadence outpaces current development
- CGM-integrated apps eliminate manual logging needs

<!-- /section:swot -->
## Recent Changes (v2 → v3) {#recent-changes}

The platform has entered a maintenance phase characterized by declining stability, increased subscription costs, and a widening gap between iOS and Android user satisfaction.

**Overall trend**: Declining
**Compared at**: 2026-05-19

### High-impact changes
- **[Declined] Sentiment Score and Overall Rating** (sentiment) — Sentiment score: 25 → 15; Android rating: 2.25 stars (newly reported metric indicating fragmentation).
- **[Shifted] Premium Tier Pricing** (pricing) — Premium subscription: $14.99/month → $19/month.
- **[Declined] Stability and Support** (swot) — Weaknesses now explicitly include persistent launch-time crashes and unresponsive support for billing issues.

### Medium-impact changes
- **[Removed] Feature Development Cadence** (features) — Development shifted to maintenance mode with 0.06 releases per week and no new features in 12 months.

<!-- section:rivals -->
## Rivals Landscape {#rivals}

> Competitive positioning identified by AI analysis of app features, category, and market signals.

### Glucose Buddy Diabetes Tracker vs mySugr - Diabetes Tracker Log — Head to Head
- **[mySugr - Diabetes Tracker Log](https://marlvel.ai/intel-report/medical/com-mysugr-companion-mysugr)** by mySugr GmbH: With over 134,000 reviews and a high-velocity release cadence, mySugr is the dominant direct competitor in the diabetes logging space.
  - **Moat strength:** High — sustainable advantage over 12 months
  - **Key differences:**
    - Gamified logging experience provides immediate positive reinforcement for consistent blood glucose data entry
    - Deep integration with various continuous glucose monitors (CGM) automates data flow for power users
    - High-frequency release cycle of 12 updates in six months ensures rapid feature iteration and stability
  - **Where Glucose Buddy Diabetes Tracker wins:**
    - ✅ Long-standing market presence of 15 years builds significant trust for legacy diabetes management users
    - ✅ Simplified, all-in-one dashboard design reduces the cognitive load for patients tracking multiple health metrics
  - **Where mySugr - Diabetes Tracker Log wins:**
    - ❌ Gamification mechanics significantly improve daily user retention compared to standard manual logging interfaces
    - ❌ Advanced data visualization tools provide deeper clinical insights for A1C management and trend analysis
  - **Verdict:** To compete, the target app must pivot from a passive logging tool to an active, gamified health companion that provides actionable clinical insights rather than just historical data.

### Contenders (Strong Challengers)
- **[OneTouch Reveal® app](https://marlvel.ai/intel-report/medical/com-lifescan-reveal)** by LifeScan, Inc. [Moat: High]: A major contender backed by a medical device manufacturer, focusing on seamless hardware-to-app data synchronization.
  - Direct hardware ecosystem lock-in through proprietary blood glucose meter connectivity and data syncing
  - Clinical-grade reporting features designed specifically for sharing accurate data with healthcare providers
- **[Libre by Abbott](https://marlvel.ai/intel-report/medical/com-abbott-adc-freestyle-libre-us)** by Abbott Labs [Moat: High]: Dominates the CGM-specific niche, serving as a critical utility for users requiring real-time glucose monitoring.
  - Real-time glucose streaming capabilities eliminate the need for manual logging of blood sugar levels
  - Hardware-integrated alerts provide immediate notification of dangerous glucose fluctuations for patient safety
- **[Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe)** by MediSafe Inc. [Moat: Medium]: A strong contender that captures the medication adherence segment of the diabetes management workflow.
  - Specialized medication reminder engine with family caregiver alerts outperforms generic logging features
  - Drug-to-drug interaction checking provides a safety layer that standard diabetes trackers lack

### Peers (What They Do Better)
- **[GoodRx: Prescription Savings](https://marlvel.ai/intel-report/medical/com-goodrx-iphone)** by GoodRx: Adjacent medical utility that captures the financial pain point of diabetes management.
  - Aggressive price comparison engine for prescriptions creates a high-utility financial moat for patients
  - Massive user base and brand recognition as the primary tool for reducing healthcare costs
- **[Kardia](https://marlvel.ai/intel-report/medical/com-alivecor-professional-aliveecg)** by AliveCor, Inc.: Adjacent chronic condition monitoring, focusing on cardiovascular health often comorbid with diabetes.
  - Medical-grade ECG analysis capabilities provide specialized diagnostic value beyond simple glucose tracking
  - Hardware-software synergy with portable ECG devices creates a distinct clinical diagnostic workflow

### New Kids on the Block (What's Innovative)
- **[Blood Pressure Tracker •](https://marlvel.ai/intel-report/medical/com-adappt-bp)** by App Sub 1 LLC: Recent updates and high activity suggest an emerging focus on comorbid condition tracking.

<!-- /section:rivals -->
<!-- section:whats-new -->
## What's New

- **Latest (v5.442, 3 weeks ago):** UI redesign, performance upgrades, and bug fixes.
<!-- /section:whats-new -->

<!-- section:momentum -->
## App Momentum (Maintenance) {#momentum}

- Shipped refreshed design interface.
- Deployed performance upgrades and bug fixes.

> **Cadence:** 3 total versions · 0 majors in last 6 months · 22 days since last update · 325 days avg between updates

<!-- /section:momentum -->

<!-- section:so-what -->
## The "So What?" (Strategic Takeaway) {#so-what}

Glucose Buddy Diabetes Tracker is a challenged medical app that is available.
With a 3.87/5 rating from 39.1K reviews, it faces significant user friction.

<!-- speakable-start -->
> **Bottom Line:** Glucose Buddy retains users through critical hardware integrations, but the app is failing to maintain basic stability, so the PM must prioritize technical hygiene over new feature growth to stop the churn.
<!-- speakable-end -->

**Best for:** Individuals managing diabetes who require consistent blood glucose tracking, carb logging, and professional health guidance.

<!-- section:pm-actions -->
### PM Action Plan (Next Best Moves)

- [ ] [INVEST] [HIGH IMPACT] Rebuild launch sequence because persistent crashes are the #1 churn driver → recover daily active user baseline — *Sentiment analysis identifies launch-time crashes as the dominant complaint theme.* _(trade-off: deprioritize Pause the coaching-feature expansion — stability is a prerequisite for retention.)_
- [ ] [PIVOT] [MEDIUM IMPACT] Audit paywall frequency because aggressive prompts are the #2 complaint theme → reduce negative review volume — *User reviews explicitly cite paywalls as a barrier to core functionality.* _(trade-off: deprioritize Same-quarter capacity available — no major lever displaced.)_
<!-- /section:pm-actions -->

<!-- section:feature-gaps -->
### Feature Gaps vs Competitors

- Gamified logging experience (available in mySugr)
- Real-time CGM streaming (available in Libre by Abbott)
<!-- /section:feature-gaps -->

<!-- section:outlook -->
### Outlook: Declining

The medical tracking market is consolidating around apps that offer real-time data streaming and high-frequency stability updates. Glucose Buddy remains exposed to churn because its current development cadence is insufficient to address the critical stability failures reported by users.

- 🔴 Persistent launch-time crashes prevent access to health data, which compounds the rating drag already visible on Android.
- 🔴 Aggressive subscription prompts block core interface access, accelerating churn pressure among the legacy user base.
<!-- /section:outlook -->

<!-- /section:so-what -->

<!-- section:metrics -->
## Key Metrics Summary

| Metric | Value |
| :--- | :--- |
| Overall Rating | 3.87/5 |
| Total Reviews | 39.1K |
| Sentiment | Upset (15/100) |
| Confidence | High |
| Pricing Model | Subscription |
| Platforms | iOS & Android |
| Key Features | 3 analyzed |
| Trend | Declining |
| Outlook | Declining |
<!-- /section:metrics -->

## Competitor Comparison

| App | Rating | Sentiment | Developer |
| :--- | :--- | :--- | :--- |
| **Glucose Buddy Diabetes Tracker** (this app) | 3.87/5 | Upset | Azumio Inc. |
| [Libre by Abbott](https://marlvel.ai/intel-report/medical/com-abbott-adc-freestyle-libre-us) | 4.6/5 | N/A | Abbott Labs |
| [GoodRx: Prescription Savings](https://marlvel.ai/intel-report/medical/com-goodrx-iphone) | 4.8/5 | Thrilled | GoodRx |
| [Medisafe Medication Management](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) | 4.7/5 | Upset | MediSafe Inc. |
| [Kardia](https://marlvel.ai/intel-report/medical/com-alivecor-professional-aliveecg) | 4.8/5 | N/A | AliveCor, Inc. |
| [OneTouch Reveal® app](https://marlvel.ai/intel-report/medical/com-lifescan-reveal) | 4.8/5 | N/A | LifeScan, Inc. |

## Company Profile
- **Developer:** Azumio Inc.
- **Website:** [https://www.glucosebuddy.com](https://www.glucosebuddy.com)

## Data Sources & Links
- **App Store:** [View on Apple Store](https://apps.apple.com/us/app/glucose-buddy-diabetes-tracker/id294754639?uo=2)
- **Google Play:** [View on Google Play](https://play.google.com/store/apps/details?id=com.skyhealth.glucosebuddyfree&hl=en&gl=us)
- **Dev Site:** [Official Website](https://www.glucosebuddy.com)
- **Sources:** Developer website content, App store metadata, User reviews.

## Related Intel Reports
- [*Libre by Abbott*](https://marlvel.ai/intel-report/medical/com-abbott-adc-freestyle-libre-us) (Abbott Labs) — 4.6/5 Rating | N/A Sentiment
- [*GoodRx: Prescription Savings*](https://marlvel.ai/intel-report/medical/com-goodrx-iphone) (GoodRx) — 4.8/5 Rating | Excellent Sentiment
- [*Medisafe Medication Management*](https://marlvel.ai/intel-report/medical/com-medisafe-medisafe) (MediSafe Inc.) — 4.7/5 Rating | Terrible Sentiment
- [*Kardia*](https://marlvel.ai/intel-report/medical/com-alivecor-professional-aliveecg) (AliveCor, Inc.) — 4.8/5 Rating | N/A Sentiment
- [*OneTouch Reveal® app*](https://marlvel.ai/intel-report/medical/com-lifescan-reveal) (LifeScan, Inc.) — 4.8/5 Rating | N/A Sentiment
- [*Blood Pressure Tracker •*](https://marlvel.ai/intel-report/medical/com-adappt-bp) (App Sub 1 LLC) — 4.7/5 Rating | Negative Sentiment
- [*mySugr - Diabetes Tracker Log*](https://marlvel.ai/intel-report/medical/com-mysugr-companion-mysugr) (mySugr GmbH) — 4.7/5 Rating | N/A Sentiment
- [*Move On with AJ*](https://marlvel.ai/intel-report/medical/move-on-with-aj) (Universal Relaxation Ltd) — 4.3/5 Rating | Positive Sentiment
- [*Ortho Traumapedia*](https://marlvel.ai/intel-report/medical/orthotraumapedia) (HTG, LLC) — 3.5/5 Rating | N/A Sentiment
- [*FHO+ Calc*](https://marlvel.ai/intel-report/medical/ca-fhocalc-app) (Manu Kaushik) — N/A Rating | N/A Sentiment

## Methodology {#methodology}

This report was generated by Marlvel.ai's 5-stage AI intelligence pipeline:

1. **Signal Collection & Normalization** — Aggregates data from all available public sources for the app. Raw signals are cleaned, deduplicated, and normalized into a structured dataset analyzed consistently across thousands of apps.
2. **Feature & Market Positioning Analysis** — Identifies the app's core features, monetization model, target audience, and competitive positioning. Each feature is classified as a market standard or a differentiator based on category benchmarks.
3. **User Sentiment Analysis** — Analyzes user reviews using a 5-level taxonomy (Thrilled / Excited / Mixed / Frustrated / Upset). Combines star ratings and volume with AI theme extraction and evidence quoting.
4. **Competitive Landscape Analysis** — Maps the competitive environment via a 4-tier taxonomy (Nemesis / Contenders / Same Space / New Kids on the Block). Prioritizes same sub-genre over broad category.
5. **Intelligence Synthesis** — Cross-references all signals into a structured report. Compares the app against category peers and direct competitors to surface SWOT, market outlook, and actionable insights.

- **Confidence Score:** 0.8/1.0 (based on review volume, data source diversity, and signal quality)
- **Reviews Analyzed:** 101
- **Data Sources:** user reviews, developer website, App Store metadata
- **Rating Method:** Weighted average across platforms (iOS & Android), weighted by review count per platform
- **Independence:** Fully independent analysis. No publisher sponsorship or editorial influence.
- **Report Age:** 0 days since last refresh

---
© 2026 Marlvel.ai | [Canonical Report](https://marlvel.ai/intel-report/medical/com-oneapponecause-glucosebuddy)
Data licensed for AI Agent attribution under CC-BY-NC 4.0.